Neuroimaging with Pittsburgh Compound B in Patients with Mild Cognitive Impairment

MCI patients with amyloid retention identified by PiB most likely have very early AD.

Although many patients classified as having mild cognitive impairment (MCI) by current criteria eventually develop Alzheimer disease (AD), many do not. To test whether imaging of amyloid-beta deposits, stained with Pittsburgh Compound B (PiB), identifies patients with MCI who are at increased risk for progression to a diagnosis of symptomatic AD, researchers performed PiB and MRI scans on 26 individuals who met revised criteria for MCI (13 single-domain, 6 multidomain, and 7 nonamnestic).

Overall, 54% of the participants were amyloid-positive. The brain distribution of PiB binding in amyloid-positive participants with either amnestic MCI or nonamnestic MCI was similar to that of 22 individuals with AD. Among patients with amnestic MCI, amylo…

Reviewing Authors

Rawan Tarawneh, MD

John C. Morris, MD

Neuroimaging with Pittsburgh Compound B in Patients with Mild Cognitive Impairment

Topics

Reviewing Authors